← All X4 Pharmaceuticals, INC filings

X4 Pharmaceuticals, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
XFOR
X4 Pharmaceuticals, INC
DEF: X4 Pharma Seeks Shareholder Approval for Equity Plan, Elects Directors
X4 Pharmaceuticals, Inc. announces its 2026 Annual Meeting of Stockholders to vote on director elections, auditor ratification, an expanded equity incentive plan, and executive compensation.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
DEFA14A: X4 Pharmaceuticals Files Definitive Proxy Statement
X4 Pharmaceuticals has filed a definitive proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
DEF: X4 Pharmaceuticals Sets Date for 2025 Annual Stockholders Meeting, Proposes Director Election and Reverse Stock Split
X4 Pharmaceuticals announces its 2025 Annual Meeting of Stockholders to be held on June 9, 2025, to elect a director, ratify the selection of an independent accounting firm, and conduct a non-binding advisory vote on executive compensation.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
DEF: X4 Pharmaceuticals Proposes Reverse Stock Split to Regain Nasdaq Compliance
X4 Pharmaceuticals is seeking stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and potentially attract a broader range of investors.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
DEFA14A: X4 Pharmaceuticals Files Definitive Proxy Statement
X4 Pharmaceuticals has filed a definitive proxy statement related to its upcoming shareholder meeting.
NASDAQ
XFOR
X4 Pharmaceuticals, INC
DEF 14A: X4 Pharmaceuticals Sets Date for 2024 Annual Stockholders Meeting
X4 Pharmaceuticals will hold its annual stockholders meeting on June 10, 2024, to elect directors, ratify the selection of its accounting firm, and conduct a say-on-pay vote.